Stock comparison
Merck & Co., Inc. is 10.5x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($371.29 B vs $35.29 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 10.5x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($371.29 B vs $35.29 B).
Market value leader
MRK
Merck & Co., Inc. is 10.5x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($371.29 B vs $35.29 B).
Revenue leader
MRK
ALNY: $3.71B vs MRK: $65.01B.
Profit leader
MRK
ALNY: $313.75M vs MRK: $18.25B.
Margin leader
MRK
ALNY: 8.4% vs MRK: 28.1% net margin.
| Metric | ALNY | MRK |
|---|---|---|
| Market cap | $35.29 B | $371.29 B |
| US-listed rank | #419 | #34 |
| Revenue (latest FY) | $3.71B | $65.01B |
| Net income (latest FY) | $313.75M | $18.25B |
| Net margin | 8.4% | 28.1% |
| P/E (trailing FY) | 112.5x | 20.3x |
| SEC filings | 1,641 | 998 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 10.5x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($371.29 B vs $35.29 B).
In their latest fiscal years, ALNYLAM PHARMACEUTICALS, INC. reported $3.71B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: ALNYLAM PHARMACEUTICALS, INC. and Merck & Co., Inc., or browse the full rankings.